Navigation Links
Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
Date:3/16/2008

ailability of the subcutaneously administered combination of GAMMAGARD LIQUID with Enhanze Technology was 92 percent of the traditional, monthly intravenous administration.

"These early results are the latest demonstration of Baxter's ongoing commitment to innovation and, in particular, to advancing the science of IGIV therapy," said Hartmut J. Ehrlich, MD, vice president of Global Research and Development for Baxter's BioScience business. "While further studies are required to confirm these results, Baxter plans to initiate a pivotal Phase III trial using GAMMAGARD LIQUID with Enhanze Technology pending discussions with regulatory authorities by the beginning of 2009."

Phase I/II Trial Design and Results

The Phase I/II clinical trial was the result of an agreement between Baxter and Halozyme Therapeutics, Inc., under which Halozyme's proprietary Enhanze Technology was applied to the development of a subcutaneous route of administration for GAMMAGARD LIQUID. Halozyme's Enhanze Technology is based on recombinant human hyaluronidase (rHuPH20), which facilitates dispersion and absorption of subcutaneously injected solutions. The Phase I/II trial evaluated the safety, tolerability and pharmacokinetics of a monthly subcutaneous administration of GAMMAGARD LIQUID with Enhanze Technology in 11 PID patients in the United States. The patients were infused with varying amounts of rHuPH20 with one-, two-, three- and then four-week doses of GAMMAGARD LIQUID to determine the amount of enzyme required to enable a full monthly dose to be infused in a single site at rates equivalent to those administered in intravenous infusions. The trial also evaluated the effect of rHuPH20 on the bioavailability of GAMMAGARD LIQUID administered subcutaneously compared to intravenously.

One patient withdrew from the study, citing moderate discomfort with the one-week dose, while the 10 patients who completed the study experienced mild local reactions that were not dose
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
2. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
3. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
4. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
7. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
8. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
9. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the CL ... on Tuesday, September 9, 2014 at 12:30 p.m. ET. ... Place Hotel in New York City ...
(Date:8/29/2014)... Research and Markets  has announced the addition of ... 2014-2018" report to their offering. ... connect, support, or surround bones. There are several types ... fascia, and other fibrous tissues. Repetitive use, accidents, injuries, ... in wear and tear in these tissues. Orthopedic soft ...
(Date:8/28/2014)... 28, 2014  Rigrodsky & Long, P.A.: , ... (NYSE: LCI )? , Did you purchase your ... July 16, 2014, inclusive? , Did you lose money ... you want to discuss your rights? ... Attorney, Timothy J. MacFall , announces that a complaint has ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
(Date:8/29/2014)... As reported by GantDaily.com in the article ... Trends , Outbreaks (8/20), the National Institute on Drug Abuse ... abuse trends by turning to social media. As NIDA currently ... is also working with the University of Maryland to create ... System, which will be funded by the National Institute of ...
(Date:8/29/2014)... Orlando, Florida (PRWEB) August 29, 2014 Formed ... men with talents well beyond their years. Their sophisticated ... avid pop music listener is fortunate enough to experience every ... to leave their audience uplifted and feeling loved with the ... When asked specifically about this, the group unanimously replied - ...
(Date:8/29/2014)... 2014 Healthpointe is pleased to ... Therapy students via Clinical Rotations. Physical ... shadowing Healthpointe providers and specialists throughout their daily ... clinical experience and learn professional preparation. ... insight into several patient care techniques and expand ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Carson Hearing ... to provide hearing health care tips to local residents ... blog section will offer weekly articles from the audiologists ... topics including the latest advances in hearing restoration research, ... questions. The audiologists plan to write a new post ...
(Date:8/29/2014)... August 29, 2014 - Despite US Preventive Services ... are many barriers, several of which may be ameliorated ... researchers at NYU Langone Medical Center published online August ... Medicine ( JGIM ). , David Levine, MD, ... Internal Medicine at NYU Langone, and colleagues found that ...
Breaking Medicine News(10 mins):Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 2Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 3Health News:KAJ Brothers Commits $10,000 to International Justice Mission To End Human Sex Trafficking and Challenges Other Artists and Celebrities To Do Likewise 4Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Fort Worth Hearing Aid Leader, Carson Hearing Care, Creates Expert Blog to Discuss Important Hearing Healthcare Topics 2Health News:Fort Worth Hearing Aid Leader, Carson Hearing Care, Creates Expert Blog to Discuss Important Hearing Healthcare Topics 3Health News:Options for weight loss your primary care doctor might not know about 2
... show no lifesaving benefit over bare-metal version, studies show ... arteries propped open by drug-coated stents are less likely ... stents, the risk of death and heart attacks is ... Sweden and the United States show. , The Swedish ...
... Week 2009, Home Care Delivered reinforces programs designed to support clinicians ... ... VA (Vocus) May 6, 2009 -- In conjunction with the American ... observed annually from May 6th through 12th. The week begins with ...
... Contributions emphasize need for improved mental health services ... The Regence Foundation announced today it awarded $390,000 ... Idaho, Oregon, Utah and Washington. Five of the ... organizations nominated by Regence employees as part of ...
... 6 Cardinal Health, a global provider of ... productivity of health care, today announced its board ... shareholders to vote on a proposed employee stock ... 99th consecutive regular quarterly dividend.The proposed option exchange ...
... now has within its reach the potential to end ... in Geneva, the Board of Directors of the Global ... today agreed to enhance the Fund,s response to HIV/AIDS ... mother-to-child transmission of HIV (PMTCT), thereby opening the door ...
... Alliance Calls for Cross-Sector Solutions, Releases Strategy ReportWASHINGTON, ... the pharmaceutical industry, patients, consumer groups, and drug ... to counter the continued rise in prescription drug ... result of a combination of factors and can ...
Cached Medicine News:Health News:Drug-Coated Stents Better at Keeping Arteries Open 2Health News:Drug-Coated Stents Better at Keeping Arteries Open 3Health News:Home Care Delivered, Inc. Celebrates National Nurses Week 2009 in Recognition of America's 2.9 Million Registered Nurses 2Health News:Regence Foundation Grants $390,000 to Improve Health Care Safety Net 2Health News:Regence Foundation Grants $390,000 to Improve Health Care Safety Net 3Health News:Cardinal Health Board Proposes Employee Stock Option Exchange Program, Declares Regular Quarterly Dividend 2Health News:Cardinal Health Board Proposes Employee Stock Option Exchange Program, Declares Regular Quarterly Dividend 3Health News:Cardinal Health Board Proposes Employee Stock Option Exchange Program, Declares Regular Quarterly Dividend 4Health News:Cardinal Health Board Proposes Employee Stock Option Exchange Program, Declares Regular Quarterly Dividend 5Health News:GAA Applauds Global Fund's Decision to Accelerate Support for Treatment Strategies to Prevent Mother-to-Child Transmission of HIV 2Health News:Prescription Drug Abuse Poses Public Health Threat 2
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
The TVL-ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margi...
... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
Medicine Products: